Indeed, trials in patients with EGFR-mutant or ALK-rearranged NSCLC have had much higher rates of crossover from chemotherapy to personalized treatment after platinum-based chemotherapy progression (65% in EGFR-mutant [19] and 70% in ALK-positive populations [20]), leading to a lack of survival differences between treatment arms. This evidence concerns the gene EGFR and non-small cell lung carcinoma.